BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES

1 . A compound of formula (I)

wherein

R 1 is 9- or 10-membered bicyclic heteroaryl wherein the 9- or 10-membered bicyclic heteroaryl contains from one to three heteroatoms independently selected from oxygen and nitrogen and is optionally substituted by C 1-6 alkyl, C 3-6 cycloalkyl, halo or —CN; or pyridinyl optionally substituted by one or two substituents independently selected from C 1-6 alkyl, —OR 4 , halo, and —NHSO 2 R 5 ;

R 2 is —NHCOR 6 ,

R 3 is hydrogen or fluoro;

R 4 and R 7 are each independently hydrogen or C 1-6 alkyl;

R 5 is C 1-6 alkyl or phenyl optionally substituted by one or two substituents independently selected from C 1-6 alkyl, halo, —CF 3 and —OR 7 ;

R 6 is 5-membered heteroaryl wherein the 5-membered heteroaryl contains from one to three heteroatoms independently selected from oxygen, nitrogen and sulphur and is substituted by —CH 2 NR 8 R 9 , —CH 2 tetrahydropyran or —CH 2 phenyl wherein the phenyl is substituted by halo; —(CH 2 ) n NR 10 R 11 ; or —CH 2 tetrahydropyran;

R 8 and R 9 , together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl or a 9-membered bicyclic heterocyclyl wherein the 6-membered heterocyclyl and the 9-membered bicyclic heterocyclyl each optionally containing a further nitrogen atom and the 6-membered heterocyclyl is substituted by three C 1-6 alkyl substituents;

R 10 and R 11 , together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl optionally containing an oxygen atom; and

n is 1, 2 or 3;

or a salt thereof.

2 . A compound according to claim 1 wherein R 1 is 9-membered bicyclic heteroaryl wherein the 9-membered bicyclic heteroaryl contains from one to three heteroatoms independently selected from oxygen and nitrogen and is optionally substituted by C 1-6 alkyl, halo or —CN; or pyridinyl optionally substituted by one or two substituents independently selected from C 1-6 alkyl, —OR 4 , halo, and —NHSO 2 R 5 .

3 . A compound according to claim 1 wherein R 1 is pyridinyl optionally substituted by one or two substituents independently selected from —OR 4 , halo, and —NHSO 2 R 5 .

4 . A compound according to claim 1 wherein R 2 is —NHCOR 6 .

5 . A compound according to claim 1 wherein R 3 is hydrogen.

6 . A compound which is:

2-[(8aS)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-ylmethyl]-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide;

2-{[(3R,5S)-3,5-dimethyl-4-(1-methylethyl)-1-piperazinyl]methyl}-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1,3-thiazole-4-carboxamide;

2-{[(3R,5S)-3,5-dimethyl-4-(1-methylethyl)-1-piperazinyl]methyl}-N-(6-{6-(methyloxy)-5-[(methylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-1,3-thiazole-4-carboxamide;

N-(6-{6-(methyloxy)-5-[(methylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-3-carboxamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1-(tetrahydro-2H-pyran-4-ylmethyl)-1H-pyrazole-5-carboxamide;

1-[(2-chlorophenyl)methyl]-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1H-pyrazole-3-carboxamide;

1-[(4-chlorophenyl)methyl]-N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-1H-pyrazole-3-carboxamide;

6-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one;

6-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-(tetrahydro-2H-pyran-4-yl)acetamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-(1-piperidinyl)acetamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-4-(4-morpholinyl)butanamide;

N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-(4-morpholinyl)acetamide;

2-(4-morpholinyl)-N-(6-{5-[(phenylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)acetamide;

N-(6-{6-chloro-5-[(methylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-(4-morpholinyl)acetamide;

N-(6-{6-methyl-5-[(methylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-(4-morpholinyl)acetamide;

N-(6-{5-[(methylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-(4-morpholinyl)acetamide;

N-(6-{6-chloro-5-[(phenylsulfonyl)amino]-3-pyridinyl}-1H-indazol-4-yl)-2-(4-morpholinyl)acetamide;

N-[6-(6-fluoro-1H-indol-4-yl)-1H-indazol-4-yl]-2-(4-morpholinyl)acetamide;

N-[3-fluoro-6-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-indazol-4-yl]-2-(4-morpholinyl)acetamide;

N-[3-fluoro-6-(1H-indol-4-yl)-1H-indazol-4-yl]-2-(4-morpholinyl)acetamide; or

a salt thereof.

7 . A compound according to claim 1 the form of a pharmaceutically acceptable salt thereof.

8 . A pharmaceutical composition comprising a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

9 - 11 . (canceled)

12 . A method of treating a disorder mediated by inappropriate PI3-kinase activity comprising administering a safe and effective amount of a compound as defined in claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

13 . A method according to claim 12 wherein the disorder mediated by inappropriate PI3-kinase activity is a respiratory disease; an allergic disease; an autoimmune disease; an inflammatory disorder; a cardiovascular disease; a hematologic malignancy; cystic fibrosis; a neurodegenerative disease; pancreatitis; multiorgan failure; kidney disease; platelet aggregation; cancer; sperm motility; transplantation rejection; graft rejection; lung injury; or pain.

14 . A method according to claim 12 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, cystic fibrosis, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trama), trigeminal neuralgia or central pain.

15 . A method according to claim 12 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma.

16 . A method according to claim 12 wherein the disorder mediated by inappropriate PI3-kinase activity is COPD.